Eurofins Cerep

ALECR.PA maintains a strong liquidity position with a current ratio of 6.85, indicating the company can easily cover its short-term liabilities with its current assets. The company's capital structure is largely equity-driven, with total equity of EUR 71.74 million and long-term debt of EUR 328,520, resulting in a debt-to-equity ratio of 0.0. This suggests a conservative leverage approach, which is typical for firms in the healthcare diagnostics industry.

In terms of profitability, ALECR.PA reports a return on equity (ROE) of 9.97% and a return on assets (ROA) of 8.51%. These figures are strong and suggest the company is effectively utilizing its equity and assets to generate returns. The gross profit of EUR 34.66 million and operating income of EUR 4.80 million further support the company's profitability.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no geographic diversification data provided, but the company's operations are likely centered in its home market. This concentration may pose a risk if the company's primary market experiences economic downturns or regulatory changes.

Looking ahead, ALECR.PA is expected to maintain its current revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's recent financial performance has been stable, with consistent revenue and profit figures. However, the absence of detailed growth projections suggests a cautious outlook.

The risk assessment for ALECR.PA indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value.

Recent filings and transcripts do not indicate any major events or strategic shifts for ALECR.PA. The company's financial statements and disclosures are consistent with its historical performance, and there are no immediate signs of distress or significant operational changes.